---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011629"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:50:52.262890+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix signs $1.1M R&D deal with Veranex for next-gen UroShield, PainShield

## Summary
- Entered into agreement with Veranex for R&D services for next-gen UroShield and PainShield; term ~50 weeks; fee up to ~$1.1M.
- Fee payable monthly, due 45 days after invoice; late fee 1.5% per month; Veranex may suspend services if payment not made.
- Either party may terminate on 60 days' notice; Veranex can also terminate for repeated late payments or relationship issues.
- CEO Brian Murphy stated partnership aims to add therapeutic functionality and reduce cost of goods; press release dated March 28, 2024.

## SEC filing metadata
- accession: 0001493152-24-011629
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/0001493152-24-011629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011629
- JSON: https://secwatch.observer/filing/0001493152-24-011629.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011629.txt

## Key facts
- Material Agreements
  ENvue Medical, Inc. entered into Agreement with Veranex, Inc. valued at approximately $1.1 million (effective 2024-03-22).
  - Action: entry
  - Counterparty: Veranex, Inc.
  - Value: approximately $1.1 million
  - Effective: 2024-03-22
  source text: On March 22, 2024, NanoVibronix, Inc., a New York corporation, (the “Company”), entered into a standalone services agreement (the “Agreement”), by and between the Company and Veranex, Inc., a Delaware corporation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/0001493152-24-011629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.